Delivery Order SPE2DB20D3303-SPE2DB25FA1YU
- Not listed
- The Defense Logistics Agency awarded a $11,636.00 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of GAMUNEX-C 40 gram/400 mL vials. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 14, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. GAMUNEX-C is an intravenous immunoglobulin (IVIG) therapy used to treat various immunodeficiency and autoimmune conditions, making it a critical...
- The U.S. Department of Defense, through its Medical Supply Chain division, awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of GAMUNEX-C 20 gram/200 milliliter vials valued at $56,646.72. This is a firm fixed-price, non-set-aside contract with a completion date of August 25, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. GAMUNEX-C is an immune globulin intravenous (human) treatment used for immunodeficiency and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of GAMUNEX-C 10 gram/100 milliliter vials, with a ceiling value of $9,157.05 and an ultimate completion date of August 22, 2025. This firm fixed-price delivery order represents a non-competitive set-aside and will be performed at the contractor's facility in Conshohocken, Pennsylvania. GAMUNEX-C is an intravenous immunoglobulin used to treat immunodeficiency and autoimmune...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of GAMUNEX-C 5 gram/50 milliliter vials valued at $3,036.70. This non-competitive delivery order, which must be completed by August 15, 2025, represents a firm fixed-price transaction under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of GAMUNEX-C (40 gram/400 mL vial) with a ceiling value of $2,327.20. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of August 20, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $7,080.84 delivery order contract to AmerisourceBergen Drug Corp for GAMUNEX-C (Immune Globulin Intravenous [Human]), a specialized pharmaceutical product supplied in 20 gram/200 milliliter vials. This firm fixed-price, non-set-aside contract is scheduled for completion by August 15, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine replenishment order under...
- The Defense Logistics Agency awarded a $23,272 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of GAMUNEX-C 40 gram/400 mL vials. This non-set-aside contract, which carries an ultimate completion date of August 20, 2025, is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a $4,555.05 delivery order to AmerisourceBergen Drug Corp for GAMUNEX-C 5 gram/50 milliliter vials on August 1, 2025, with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $41,178.10 on July 24, 2025, for the supply of GAMUNEX-C 40 gram/400 milliliter vials. This competitively awarded, firm fixed-price contract carries an ultimate completion date of August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order was issued without a set-aside designation, reflecting open competition among qualified...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of GAMUNEX-C 20 gram/200 milliliter vials valued at $11,651.54 under a firm fixed-price contract with an ultimate completion date of August 18, 2025. This non-set-aside award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA1YUDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of GAMUNEX-C 40 Gram/400 mL vials, valued at $4,654.40 with a firm fixed price structure. This is an unset-aside, competitively awarded contract with an ultimate completion date of August 20, 2025, and performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. GAMUNEX-C is an intravenous immunoglobulin (IVIG) product used to treat primary immunodeficiency and other immune-related conditions, representing a critical pharmaceutical supply for military and federal healthcare systems. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999 prime vendor agreement extending through December 2026. As one of the Department of Defense's primary pharmaceutical distributors, AmerisourceBergen supplies a comprehensive range of medications and medical commodities to support military healthcare programs globally. The company's significant IDC with DLA reflects its established capability to meet federal procurement requirements through competitive processes and demonstrates its role as a critical vendor for the Defense Health Agency and other federal healthcare entities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 7/30/25 |